Pacific Edge’s product pipeline shows the significant progress since its inception. We are constantly moving the discoveries through the pipe towards commercialisation whilst continuing the focus on the process of discovery.

Diagnostic and prognostic key milestones –

gastric, bladder and colorectal cancer

Gastric cancer	2005:	Monoclonal antibodies developed for two target antigens Grants awarded for $1.04 million over 18 months to build multiple bio-marker diagnostic assay Japanese partners in negotiation
	2004:	30,000 genes screened 29 excellent candidate markers identified 12 ‘best’ selections made
Bladder cancer:	2005:	Beta product developed to differentiate tumours from normal tissue Beta product validated for differentiation of superficial and invasive sub-types Japanese and American partners in negotiation
	2004:	30,000 genes screened 18 best selections made
Colorectal cancer:	2005:	Gene signatures developed for prognostic tool development International Collaboration with the Department of Surgery, Technical University Munich to define signatures for aggressive forms of the disease

New projects are also under development:

1. An exciting project has been initiated in 2005 on the development of a prognostic tool for malignant melanoma with the Ludwig Institute for Cancer Research based in Melbourne.
2. The colorectal cancer project has recently delivered results that may lead to a new tool that predicts the probability of rapid disease progression.
3. A recent discovery made in collaboration with scientists in the Cancer Genetics Laboratory, Dept of Biochemistry, University of Otago has identified a gene involved in apoptosis. Apoptosis is the genetically pre-programmed mechanism for the death of aged or damaged cells. In cancer this mechanism no longer operates correctly and can be a target for development of therapeutic products. This gene’s role as a potential therapeutic is currently under evaluation.